LimFlow Appoints Mike Mathias as Vice President, Commercial Operations

December 6, 2022—LimFlow SA, a France-based developer of minimally invasive technology for the treatment of chronic limb-threatening ischemia, announced the appointment of Mike Mathias as Vice President of Commercial Operations. The move comes as the company is preparing for the anticipated launch of the LimFlow system in the United States.

Additionally, Theo Mastrokostopoulos, who is currently Vice President of Global Sales and Market Development, is being appointed to General Manager, International to lead all commercial activity outside of the United States.

The LimFlow system received CE Mark approval and is currently available commercially in Europe. The LimFlow system has not been approved for sale in the United States, Canada, or Japan. Currently, the LimFlow technology is approved in the United States for investigational use only.

LimFlow CEO Dan Rose commented in the press release, “Mike is an extraordinary leader with deep experience building successful sales teams and commercializing innovations such as transcatheter aortic valve replacement (TAVR), where he introduced a transformational new device and therapy into a complex market development setting in the United States. The magnitude of our opportunity at LimFlow has enabled us to attract the highest level of talent to our team and we look forward to benefitting from Mike’s insights and sales leadership as we build our commercial organization and prepare for the future launch of the LimFlow system in the United States.”

According to LimFlow, Mr. Mathias’ 30-year career of leading sales organizations in the cardiovascular space, includes the launch of Medtronic’s TAVR business as head of the company’s $1.2 billion Heart Valve Therapies United States sales operation. Most recently, he was Vice President of United States Commercial Operations for the Medtronic Structural Heart division, leading sales, marketing, training, and sales operations.

He earned a BS in Arabic and French Studies at the United States Military Academy at West Point and holds an MBA from the University of Minnesota.

“I see many parallels between LimFlow and the groundbreaking solution that TAVR represented for both patients and physicians,” commented Mr. Mathias in the company’s press release. “LimFlow can be an equally revolutionary therapy with the potential to significantly reduce amputations due to end-stage vascular disease and change the course of patient care. The patient-centric culture of execution at LimFlow combined with the collaborative nature of the skilled team provides a strong foundation to build the United States commercial organization at LimFlow.”